Antibiotic prophylaxis during chemotherapy-induced neutropenia for patients with acute leukemia

Current Hematologic Malignancy Reports

Volumn 2, Issue 2, 2007, Pages 97-103

  Hammond, Sarah P ^a   Baden, Lindsey R ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CIPROFLOXACIN; COTRIMOXAZOLE; ENOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACUTE LEUKEMIA; ADULT RESPIRATORY DISTRESS SYNDROME; ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; CANCER CHEMOTHERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED CLINICAL TRIAL; DESQUAMATION; DISEASE PREDISPOSITION; DRUG INDUCED DISEASE; ESCHERICHIA COLI; FEBRILE NEUTROPENIA; FEVER; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; HUMAN; HYPOTENSION; INFECTION COMPLICATION; INFECTION PREVENTION; INFECTION RISK; META ANALYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORBIDITY; MORTALITY; MUCOSA INFLAMMATION; MYCOSIS; NEUTROPENIA; PALM DESQUAMATION; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; SEPTIC SHOCK; SOLE DESQUAMATION; SYSTEMATIC REVIEW; TREATMENT FAILURE;

ACUTE DISEASE; ANTIBIOTIC PROPHYLAXIS; ANTINEOPLASTIC AGENTS; DISEASE SUSCEPTIBILITY; DOUBLE-BLIND METHOD; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; LEUKEMIA; NEUTROPENIA; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNNECESSARY PROCEDURES;

EID: 34248402480     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-007-0014-2     Document Type: Review

References (45)

1. Bow EJ: Infectious complications in patients receiving cyto toxic therapy for acute leukemia: history, background and approaches to management. In Management of Infection in Oncology Patients. Edited by Wingard JR, Bowden RA. London: Martin Dunitz; 2003:71-104.
2. Hughes WT, Armstrong D, Bodey GP, et al.: 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34:730-752.
3. Bodey GP, Buckley M, Sathe YS, Freireich EJ: Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966, 64:328-340.
4. • Loo VG, Poirier L, Miller MA, et al.: A predominately clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005, 353:2442-2449. A prospective description of the rate of nosocomial C. difficile-associated diarrhea in 12 hospitals, which also included a case-control study to identify the major risk factors for C. difficile-associated diarrhea. Previous exposures to fluoroquinolones or cephalosporins were the most important risk factors identified.
5. McDonald LC, Killgore GE, Thompson A, et al.: An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005, 353:2433-2441.
6. Glynn MK, Reddy V, Hutwagner L, et al.: Prior antimicrobial agent use increases the risk of sporadic infections with multidrug-resistant Salmonella enterica serotype typhimurium: a FoodNet case-control study, 1996-1997. Clin Infect Dis 2004, 38:S227-S236.
7. Olsen SJ, DeBess EE, McGivern TE, et al.: A nosocomial outbreak of fluoroquinolone-resistant salmonella infection. N Engl J Med 2001, 344:1572-1579.
8. Huotari K, Tarkka E, Valtonen V, Kolho E: Incidence and risk factors for nosocomial infections caused by fluoroquinolone-resistant Escherichia coli. Eur J Clin Microbiol Infect Dis 2003, 22:492-495.
9. •• Bucaneve G, Micozzi A, Menichetti F, et al.: Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005, 353:977-987. A randomized, double-blind, placebo-controlled trial of prophylactic levofloxacin in 760 adult patients undergoing chemotherapy expected to cause neutropenia for more than 7 days, which showed a significant reduction in fever and microbiologically documented infection but no significant difference in mortality. Patients treated with levofloxacin had significantly more infections with levofloxacin-resistant gram-negative organisms.
10. •• Cullen M, Steven N, Billingham L, et al.: Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005, 353:988-998. A randomized, double-blind, placebo-controlled trial of prophylactic levofloxacin in 1565 adult patients undergoing cyclical chemotherapy for solid tumor or lymphoma expected to result in neutropenia. The trial showed a significant reduction in febrile episodes and hospitalization. There was no difference in the rate of severe infection or mortality.
11. Zinner SH: Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 1999, 29:490-494.
12. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB: Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003, 36:1103-1110.
13. Enno A, Darrell J, Hows J, et al.: Co-trimoxazole for prevention of infection in acute leukaemia. The Lancet 1978, 2:395-397.
14. Gualtieri RJ, Donowitz GR, Kaiser DL, et al.: Double-blind randomized study of prophylactic trimethoprim-sulfa-methoxazole in granulocytopenic patients with hematologic malignancies. Am J Med 1983, 74:934-940.
15. Lo N, Cullen M: Antibiotic prophylaxis in chemotherapy-induced neutropenia: time to reconsider. Hematol Oncol 2006, 24:120-125.
16. Bow EJ, Mandell LA, Louie TJ, et al.: Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented gram-positive activity on infectious morbidity. Ann Intern Med 1996, 125:183-190.
17. Cruciani M, Rampazzo R, Malena M, et al.: Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 1996, 23:795-805.
18. Engels EA, Lau J, Barza M: Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998, 16:1179-1187.
19. Gafter-Gvili A, Fraser A, Paul M, et al.: Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 2005, 4:CD004386.
20. Gafter-Gvili A, Fraser A, Paul M, Leibovici L: Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005, 142:979-995.
21. Karp JE, Merz WG, Hendricksen C, et al.: Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. Ann Intern Med 1987, 106:1-7.
22. Leibovici L, Paul M, Cullen M, et al.: Antibiotic prophylaxis in neutropenic patients. Cancer 2006, 107:1743-1751.
23. Reuter S, Kern WV, Sigge A, et al.: Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. Clin Infect Dis 2005, 40:1087-1093.
24. Talbot GH, Cassileth PA, Paradiso L, et al.: Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukemia. Antimicrob Agents Chemother 1993, 37:474-482.
25. Ray TG, Baxter R, DeLorenze GN: Hospital-level rates of fluoroquinolone use and the risk of hospital-acquired infection with ciprofloxacin-nonsusceptible Pseudomona aeruginosa. Clin Infect Dis 2005, 41:441-449.
26. Baden LR: Prophylactic antimicrobial agents and the importance of fitness. N Engl J Med 2005, 353:1052-1054.
27. Carratala J, Fenandez-Sevilla A, Tubau F, et al.: Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 1995, 20:557-560.
28. Cometta A, Calandra T, Bille J, et al.: Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia [letter]. N Engl J Med 1994, 330:1240-1241.
29. Kern WF, Andriof E, Oethinger M, et al.: Emergence of fluoroquinolone resistant Escherichia coli at a cancer center. Antimicrob Agent Chemother 1994, 38:681-687.
30. Kern WV, Klose K, Jellen-Ritter AS, et al.: Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroqui-nolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis 2005, 24:111-118.
31. • Kern WV, Steib-Bauert M, de With K, et al.: Fluoroquinolone consumption and resistance in haematology-oncology patients: ecological analysis in two university hospitals 1999-2002. J Antimicrob Chemother 2005, 55:57-60. A comparison of the rates of fluoroquinolone-resistant E. coli among cancer patients at two different hospitals-one with high fluoroquinolone use (fluoroquinolone prophylaxis) and another with low quinolone use (trimethoprim-sulfamethoxazole prophylaxis). Rates of bloodstream infection due to fluoroquinolone-resistant E. coli correlated with fluoroquinolone use.
32. Oethinger M, Jellen-Ritter AS, Conrad S, et al.: Colonization and infection with fluoroquinolone-resistant Escherichia coli among cancer patients: clonal analysis. Infection 1998, 26:379-384.
33. Hooper DC: Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis 2001, 7:337-341.
34. Gomez L, Garau J, Estrada C, et al.: Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of ciprofloxacin-resistant Escherichia coli. Cancer 2003, 97:419-424.
35. Freifeld A, Marchigiani D, Walsh T, et al.: A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999, 341:305-311.
36. Kern WV, Cometta A, de Bock R, et al.: Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med 1999, 341:312-318.
37. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB: Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms. Clin Infect Dis 2003, 36:1103-1110.
38. Gonzalez-Barca E, Fernandez-Sevilla A, Carratala J, et al.: Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution. Eur J Clin Microbiol Infect Dis 1996, 15:291-296.
39. Bochud PY, Eggiman P, Calandra T, et al.: Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis 1994, 18:25-31.
40. Moran GJ, Krishnadasan A, Gorwitz RJ, et al.: Methi cillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006, 355:666-674.
41. Tunkel AR, Sepkowitz KA.: Infections caused by viridans streptococci in patients with neutropenia. Clin Infect Dis 2002, 34:1524-1529.
42. Kern W, Linzmeier K, Kurrle E: Antimicrobial susceptibility of viridans streptococci isolated from patients with acute leukemia receiving ofloxacin for antibacterial prophylaxis. Infection 1989, 17:396-397.
43. Timmers GJ, Dijstelbloem Y, Simoons-Smit AM, et al.: Pharmacokinetics and effects on bowel and throat microflora of oral levofloxacin as antibacterial prophylaxis in neutropenic patients with haematological malignancies. Bone Marrow Transplant 2004, 33:847-853.
44. Razonable RR, Litzow MR, Khaliq Y, et al.: Bacteremia due to viridans group streptococci with diminished susceptibility to levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. Clin Infect Dis 2002, 34:1469-1474.
45. Elting LS, Bodey GP, Keefe BH: Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis 1992, 14:1201-1207.